PTC THERAPEUTICS, INC. 4

Executive VP and CLO Mark Elliott Boulding exercised options and sold 5,079 shares of PTC Therapeutics, Inc. (PTCT) common stock on July 6, 2026, under a Rule 10b5-1 plan.

On July 6, 2026, Mark Elliott Boulding, Executive Vice President and Chief Legal Officer of PTC Therapeutics, Inc., exercised two tranches of stock options and sold shares under a Rule 10b5-1 plan. He exercised 2,266 options at $39.42 per share and 2,813 options at $46.54 per share, acquiring a total of 5,079 shares of common stock. In conjunction with or following these exercises, he sold an aggregate of 5,079 shares of common stock in multiple transactions at weighted-average prices ranging from approximately $83.10 to $86.38 per share, for an estimated total sale value of roughly $425,000. After these transactions, he continued to beneficially own 105,272 shares of PTC Therapeutics common stock, valued at approximately $9.1 million using prevailing sale prices as an indication of market value.

Filing Facts

CIK

1070081

Ticker

PTCT

Form

4

Source Type

fda

Accession

0001578852-26-000020

Alert Tier

6